PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Earnings for PepGen Inc. (PEPG)
Earnings in 2023 (TTM): $-78,553,000
According to PepGen Inc.'s latest financial reports the company's current earnings (TTM) are $-78,553,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of PepGen Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-78,553,000 | $-78,626,000 |
| 2022 | $-65,398,000 | $-69,104,000 |
| 2021 | $-27,281,000 | $-27,281,000 |
| 2020 | $-1,889,000 | $-1,881,000 |
| 2019 | $-1,346,000 | $-1,346,000 |